The short answer: neither form is better for everyone. The pill is a daily tablet with strict timing rules. The injection is a weekly shot with no food rules. Both carry the same cardiovascular-risk-reduction indication on their FDA labels, but the large heart-outcomes trial described in the label tested the injection. That is a fair question to raise with your prescriber, especially if you have established heart disease.
What the Label Says About Heart Outcomes
The FDA-approved Wegovy label lists, for both the tablet and the injection, an indication to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. FDA label (PDF); DailyMed.
The outcomes trial described in that label enrolled 17,604 adults with established cardiovascular disease and reported a hazard ratio of 0.80 for major cardiovascular events (95% CI 0.72 to 0.90). That trial studied the weekly injection, not the tablet. The tablet's own pivotal weight-loss trial, OASIS 4, did not measure cardiovascular outcomes. American College of Cardiology summary of OASIS 4.
In plain terms: the tablet carries the indication, but the direct heart-outcome evidence in the label comes from injection data. How much weight to give that difference is a judgment for you and your cardiology team.
Wegovy Pill vs. Injection Side by Side
Dosing schedule
- Pill: one tablet daily. Starts at 1.5 mg for 30 days, then 4 mg, then 9 mg, then a 25 mg maintenance dose, with your prescriber directing each step.
- Injection: once weekly, starting at 0.25 mg and titrating to a 2.4 mg maintenance dose.
Fasting and timing rules
- Pill: take it on an empty stomach in the morning with up to 4 ounces of water, swallow it whole (do not split, crush, chew, or dissolve it), then wait at least 30 minutes before eating, drinking, or taking other oral medicines. If you miss a dose, skip it and take the next dose the following day.
- Injection: can be given with or without meals.
Heart-outcome evidence
- Pill: labeled for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight; the tablet weight-loss trial (OASIS 4, 307 adults without diabetes) did not measure cardiovascular outcomes.
- Injection: the label's cardiovascular outcomes trial (17,604 adults) studied this form.
Common side effects
- Pill: the label says the types and frequency of common adverse reactions with the tablet were similar to those listed for the injection. In OASIS 4, gastrointestinal events occurred in 74% of the tablet group versus 42% of the placebo group, and permanent discontinuation was 6.9% versus 5.9%.
- Injection: in the label's adult table, nausea 44%, diarrhea 30%, vomiting 24%, constipation 24%, abdominal pain 20%, headache 14%.
- Both: the label lists warnings including acute pancreatitis, acute gallbladder disease, acute kidney injury from volume depletion, and increased heart rate. Both carry a boxed warning about thyroid C-cell tumors in rodents, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Cost questions
- Prices vary by pharmacy, dose, insurance, and program, and they change, so this article lists none. Ask about the cost of each dose step, not just the starting dose.
- Ask whether your plan covers the pill, the injection, both, or neither, and whether prior authorization is required.
- Ask what happens to the cost if you move up a dose or switch forms.
Can I Compare the Weight-Loss Numbers?
Be careful here. OASIS 4 reported an estimated average change in body weight of about -14% with the 25 mg tablet versus -2% with placebo at week 64, in adults without diabetes. The injection was studied in different trials with different participants, durations, and designs. The sources I reviewed did not include a head-to-head trial, so lining up percentages from separate studies can mislead. ACC summary.
5 Questions to Bring to Your Prescriber
- What does my heart history change? Ask whether your specific cardiovascular history, including any prior heart attack, stroke, or heart surgery, makes one form a better fit, and how the label's warning about increased heart rate applies to you.
- Which medicines do I take, and when? The pill requires a 30-minute wait before other oral medicines. The label notes levothyroxine exposure increased 33% in a tablet interaction study, so ask whether any of your medicines need monitoring.
- Which routine can I keep? Daily empty-stomach timing suits some mornings and not others; a weekly injection suits some people and not others. Be honest about what you will actually do.
- How will we handle side effects? Ask what to do about nausea, vomiting, or diarrhea, which symptoms need a same-day call, and how dehydration is managed.
- What will it cost over time, and what is the plan if that changes? Ask about coverage, dose-step costs, and what we do if I need to switch forms.
Who Should Seek Professional Advice First
Talk with a prescriber before starting or switching if you have established heart disease, a history of pancreatitis or gallbladder disease, kidney problems, a personal or family history of medullary thyroid carcinoma or MEN 2, or if you are pregnant or planning pregnancy (the label states weight loss offers no benefit during pregnancy and may cause fetal harm). Do not change or stop heart medicines on your own because of anything you read here.
What to Do Next
Write down your medicine list, your morning routine, and your top three questions from above before the appointment. If you are also weighing other oral GLP-1 options, our related guide, oral GLP-1 options compared: Foundayo vs. Wegovy vs. Zepbound, may help you frame them.
Sources
- FDA prescribing information, Wegovy tablets (accessdata.fda.gov)
- DailyMed: Wegovy injection and tablet label
- Manufacturer instructions for taking the Wegovy pill
- American College of Cardiology: OASIS 4 summary
Educational information only. It does not replace advice from your prescriber or cardiology team. This article does not recommend a product or provide a review.